Arisaph Pharmaceuticals

Arisaph awarded phase I STTR grant

Tuesday, August 6, 2013

Arisaph Pharmaceuticals, a privately held drug discovery and development biopharmaceutical company focused on developing novel therapies for cardiometabolic diseases and cancer, has been awarded a phase I Small Business Technology Transfer (STTR) award from the National Cancer Institute of the NIH. The award supports the R&D of Arisaph’s small molecule immune modulators to stimulate tumor immunity following treatment with BRAF inhibitors in cancer.  

[Read More]